Get to know our clinical trials

Clinical trial of navitoclax in combination with ruxolitinib compared to ruxolitinib in patients with myelofibrosis.

THE OBJECTIVE OF THIS STUDY IS TO EVALUATE THE EFFICACY OF NAVITOCLAX AND ITS SAFETY WHEN ADMINISTERED IN COMBINATION WITH RUXOLITINIB COMPARED TO RUXOLITINIB AND PLACEBO ON THEIR DISEASE IN PATIENTS WITH MYELOFIBROSIS WHO HAVE NOT PREVIOUSLY BEEN TREATED WITH A STANDARD TREATMENT SUCH AS A JAK-2 INHIBITOR OR SIMILAR DRUG. THE STUDY HAS TWO TREATMENT GROUPS AND YOU WILL BE RANDOMLY ASSIGNED TO ONE OF THE TWO TREATMENT GROUPS.

Status
reclutamiento
headquarters
Pamplona

Technical Summary

  • PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND STUDY OF NAVITOCLAX IN COMBINATION WITH RUXOLITINIB COMPARED TO RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS (TRANSFORM-1).
  • Code EudraCT: 2020-000097-15
  • Protocol number: M16-191
  • Promoter: Abbvie farmacéutica
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.